Answers are grounded in this paper and cite their sources.
Investigates B cell activation by HIV broadly neutralizing antibodies, highlighting affinity's limited predictive power.
M limits bnAb induction above a certain affinity. Using adeno-associated virus (AAV)-mediated CRISPR-Cas9 engineering to express HIV-specific bnAbs and non-bNAbs in Ramos B cells, we investigate antigen-specific activation by BCRs of known binding/neutralization potency, epitope and affinity. We found that between different bnAb epitopes affinity was not predictive of activation. However, within individual epitopes and across non-bnAb epitopes, increased affinity results in increased activation. We propose that at activation-resistant bnAb epitopes, affinity is overruled to an extent by the physical BCR-antigen interaction, while more 'simple' and immunogenic non-bnAb epitopes are more heavily dependent on BCR affinity. These findings may have significant consequences for vaccine development, as a high affinity BCR-antigen interaction at an epitope with poor activation potential may be unsuccessful at participating in the humoral response.
No takes yet. Share an insight, caveat, or question.
Rees-Spear et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: